AspenBio to Present at Canaccord Genuity Annual Growth Conference on August 9, 2011
(firmenpresse) - CASTLE ROCK, CO -- (Marketwire) -- 07/22/11 -- (NASDAQ: APPY), an emerging in-vitro diagnostic company, has been invited to present at the Canaccord Genuity 31st Annual Growth Conference. The conference will be held at the InterContinental Hotel in Boston, MA on August 9-11, 2011.
AspenBio's President and CEO, Steve Lundy, and SVP of Product Development and Manufacturing, Gregory Bennett, are scheduled to present on Tuesday, August 9, 2011 at 5:00 p.m. Eastern time, with a breakout session to follow and one-on-one meetings planned during the conference. Management will discuss the company's progress, including developments with AppyScore™, the first blood-based testing system designed to help physicians manage the millions of patients who enter emergency rooms every year complaining of abdominal pain and suspected of having acute appendicitis but at low risk for the disease.
For more information about the conference or to schedule a one-on-one meeting with AspenBio management, contact your Canaccord representative.
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc., offering institutional and corporate clients idea-driven investment banking, merger and acquisition, research, sales and trading services from 16 offices worldwide. The company's team of 375 capital markets professionals have industry and transactional expertise in critical sectors of the global economy: Metals and Mining, Energy, Agriculture, Technology, Telecommunications, Financials, Consumer Products, Real Estate, Transportation, Infrastructure, Sustainability, Life Sciences, Support Services and Investment Trusts. The company is committed to providing valued services to its clients throughout the entire lifecycle of their business and operating as a gold standard independent investment bank -- expansive in resources and reach, but targeted in industry expertise, market focus and individual client attention. For more information, go to .
AspenBio Pharma, Inc. (NASDAQ: APPY) is an emerging in-vitro diagnostic company focused on obtaining U.S. FDA clearance for its lead product, AppyScore™. AppyScore is a unique, blood-based test designed to help physicians manage the millions of patients who enter emergency rooms every year complaining of abdominal pain and suspected of having acute appendicitis but at low risk for the disease. AppyScore is a rule-out screening test with high sensitivity and negative predictive value. The test could potentially decrease radiation exposure risk arising from the use of CT scans performed in triaging pediatric and adolescent patients with abdominal pain, as well as potentially reduce healthcare costs. The company has a large and unique repository of blood samples that provide valuable data regarding the appendicitis condition and additional protein marker information associated with causes of abdominal pain, providing an important resource for product development. The company also has several reproduction drugs in research and development for use in animals of economic importance.
AspenBio Pharma has several issued or pending patents in the United States and abroad that cover its appendicitis and animal health-related technologies, including those exclusively licensed from Washington University in St. Louis.
For more information, visit .
AspenBio Pharma, Inc.
Gregory Pusey
Tel 303-794-2000 x 207
Liolios Group, Inc.
Ron Both
Tel 949-574-3860
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.07.2011 - 12:30 Uhr
Sprache: Deutsch
News-ID 36993
Anzahl Zeichen: 0
contact information:
Town:
CASTLE ROCK, CO
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 240 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AspenBio to Present at Canaccord Genuity Annual Growth Conference on August 9, 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
AspenBio Pharma, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
